Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Study sponsor: Scynexis, Inc. · SCYX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-08-25Actual
Enrollment · participants233Actual
Source updated2024-11-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.